Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290803 · ClinicalTrials.gov registry record
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
A clinical trial of Atopic Dermatitis, sponsored by Sanofi.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT07290803 is a study of Atopic Dermatitis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 1,000 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT07290803, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.
Conditions Studied
Study Locations (20)
California
- Kern Research, Inc.- Site Number : 8400047 - Bakersfield
- Center for Dermatology Clinical Research- Site Number : 8400014 - Fremont
- Dermatology Research Associates - Los Angeles- Site Number : 8400020 - Los Angeles
- Northridge Clinical Trials, LLC- Site Number : 8400009 - Northridge
- Sunwise Clinical Research, LLC.- Site Number : 8400010 - Oakland
- Empire Clinical Research, LLC- Site Number : 8400007 - Pomona
- University Clinical Trials- Site Number : 8400019 - San Diego
Michigan
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017 - Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042 - Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052 - Bay City
- The Derm Institute of West Michigan- Site Number : 8400025 - Caledonia
- Michigan Dermatology Institute - Waterford- Site Number : 8400013 - Waterford
Alabama
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006 - Birmingham
- River Region Dermatology and Laser- Site Number : 8400041 - Montgomery
Florida
- St. Jude Clinical Research- Site Number : 8400049 - Doral
- Ziaderm Research, LLC- Site Number : 8400021 - North Miami Beach
Georgia
- Skin Care Physicians of Georgia - Macon- Site Number : 8400034 - Macon
- Georgia Skin & Cancer Clinic- Site Number : 8400023 - Savannah
Arizona
- San Tan Allergy & Asthma- Site Number : 8400031 - Gilbert
Colorado
- Western States Clinical Research, Inc.- Site Number : 8400051 - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2034-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07290803
The ClinicalTrials.gov registry entry for NCT07290803 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT07290803 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Michigan, Alabama.
Frequently Asked Questions
What is clinical trial NCT07290803 about?
NCT07290803 is a clinical study titled "This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment". The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. A...
What is the current status of trial NCT07290803?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-11-17. Estimated completion is 2034-01-30.
What conditions does trial NCT07290803 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
Who is sponsoring clinical trial NCT07290803?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290803 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.